Obagi Medical Launches Nu-Cil® BioStim(TM) Scalp Serum
MWN-AI** Summary
Obagi Medical has announced the launch of Nu-Cil® BioStim™ Scalp Serum, a product designed to enhance scalp health and promote fuller hair. Launched on October 8, 2025, the serum is formulated with the BioStim™ Complex, which includes a blend of clinically proven ingredients like Biotin, Amino Acids, Peptides, and 18 essential Nutrients. This innovative leave-in serum aims to address common issues related to hair thinning and scalp health, an area of growing concern for both consumers and healthcare providers.
Clinical studies indicate the serum significantly reduces dry fallen hair by 74% within three months and promotes healthier, denser hair as early as two weeks after use. Dr. Suzan Obagi, the Chief Medical Officer of Obagi, noted the increasing prevalence of hair loss among various demographics, including those experiencing hormonal changes and nutritional deficiencies. With about two-thirds of Americans over the age of 35 facing hair loss, the product is timely in addressing these widespread concerns.
Nu-Cil® BioStim™ Scalp Serum is particularly notable for its fast-absorbing, non-greasy formula that offers a comprehensive approach to hair vitality, targeting multiple factors that compromise scalp health. The product is priced at $125 and will be available on Obagi’s website.
Justin Giouzepis, Chief Marketing Officer of Obagi, emphasized the company’s commitment to innovating within the hair care sector, aligning with consumer demands for effective, science-driven solutions. Obagi Medical, recognized as a leader in advanced skincare, seeks to empower individuals with solutions that enhance both skin and scalp care.
MWN-AI** Analysis
Obagi Medical's launch of the Nu-Cil® BioStim™ Scalp Serum marks a significant expansion into the hair care market, leveraging its established reputation in clinical skin science. This product is particularly timely, as consumer demand for hair care solutions is on the rise; approximately two-thirds of Americans over 35 experience hair thinning or loss, driving a broader interest in scalp health. The serum's formulation, incorporating Biotin, Amino Acids, Peptides, and essential nutrients, aligns with current market trends favoring high-performance, ingredient-focused products.
Investors should take note that this innovation positions Obagi to capture a share of the growing hair care and scalp treatment sector, which is increasingly influenced by medical-grade formulations. Given that 56% of women in the U.S. seek skincare-grade ingredients in their hair care products, the Nu-Cil® serum is poised to resonate well with consumers seeking scientifically backed solutions for scalp and hair health.
Moreover, the clinical efficacy reported—74% reduction in dry fallen hair within three months and significant improvements in overall hair density—provides a solid proof of concept that can drive consumer trust and ultimately sales. With a price point of $125, it also positions the product as a premium offering, potentially appealing to a demographic willing to invest in quality personal care products.
However, potential market risks include the competitive landscape of hair care and the need for effective marketing strategies to build brand recognition within this new segment. There may also be challenges associated with consumer education on the benefits of scalp health.
Overall, with strategic marketing and continuity in product efficacy, Obagi could harness this launch to enhance its market position and attract a loyal customer base, making it a potential buy for investors focused on growth in the beauty and wellness sectors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), the fastest growing professional skincare brand in the U.S. in 2024*, proudly unveils its latest innovation rooted in clinical skin science: Nu-Cil ® BioStim™ Scalp Serum. Designed to promote a healthier scalp, the foundation of fuller, stronger hair, this advanced leave-in serum is clinically proven to reduce dry, fallen hair by 74% in just three months, helping deliver visibly denser, fuller-looking strands.
The Nu-Cil ® BioStim™ Scalp Serum expands on Obagi’s 35 years of skin health expertise and leadership in medical-grade innovation by applying its skin first philosophy to the scalp through the BioStim™ Complex. The BioStim™ Complex utilizes proprietary technology powered by a synergistic blend of clinically proven actives, including Biotin, Amino Acids, and Peptides – alongside 18 essential Nutrients, B Vitamins, and Phytoactives. These actives work to promote scalp health, fortify hair follicles, and strengthen strands from the root.
Designed to target multiple factors involved in scalp health and reinforce the hair’s natural resilience, this fast-absorbing, non-greasy formula offers a comprehensive approach to help combat thinning, reduce breakage, and enhance overall hair vitality for visibly denser, fuller hair.
“In my practice, I’m seeing a rising number of patients with hair loss concerns, ranging from those with underlying hormonal contributors, such as PCOS, perimenopause, and postmenopause, to younger men aiming to maintain hair density as they age, to those with thyroid disorders or nutritional deficiencies following significant weight loss,” said Dr. Suzan Obagi, Chief Medical Officer of Obagi. “We’re excited about the launch of Nu-Cil ® BioStim™ Scalp Serum because it was designed to address these concerns. It was evaluated in a six-month, double-blind clinical study, with results showing that participants using Nu-Cil ® BioStim™ Scalp Serum experienced meaningful improvements as early as two weeks into treatment.”
Hair loss and thinning have become top concerns among both consumers and providers: two in three Americans over age 35 experience hair loss or thinning.** At the same time, the professional aesthetics space is evolving: 56% of U.S. women now seek skincare-grade ingredients in their hair care***, with more U.S. physicians offering services and products addressing hair restoration.****
A clinical study demonstrated the efficacy of Nu-Cil ® BioStim™ Scalp Serum, with participants experiencing significant improvements in scalp health:
- In just 2 weeks, clinically proven* to help:
- Decrease the amount of wet and dry fallen hair
- Re-deliver hydration to the scalp
- Reduce hair breakage when dry combing
- In just 3 months, clinically proven* to help:
- Reduce the amount of dry fallen hair by 74%**
- Reduce hair breakage when dry combing by 74%**
- Increase hair count per cm2 by 2.8%**
- In less than 6 months, clinically proven* to help:
- Significantly improve hair volume by 52%******
- Significantly decrease the amount of dry fallen hair by 97% ********
“At Obagi, we’re always striving to innovate and deliver transformative results across every facet of skincare and now scalp care,” said Justin Giouzepis, Chief Marketing Officer of Obagi. “We’re proud to introduce Nu-Cil ® BioStim™ Scalp Serum as a powerful solution for individuals experiencing hair thinning, scalp imbalance, or age-related changes. This launch reflects our commitment to meeting evolving consumer needs with science-driven, high-performance formulas.”
The Nu-Cil ® BioStim™ Scalp Serum, priced at $125 will be available for purchase on Obagi.com .
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm ® System, Obagi products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,* Obagi empowers individuals to achieve healthy, beautiful skin. The brand continues to lead in physician-recommended skincare solutions and was recognized as the #1 Physician-Recommended Brand for At-Home Skincare Products for Hyperpigmentation, Fine Lines & Wrinkles, and Sagging Skin & Loss of Elasticity.** More information about Obagi is available on the brand’s website, https://www.obagi.com .
*Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
**Dermatology & Cutaneous Surgery Institute (DCSI) in January 2022, Source: https://www.fortunebusinessinsights.com/hair-care-market-102555
***U. S.: 1,006 female internet users aged 18+ who use shampoo or conditioner products. Source: Kantar Profiles/Mintel, January 2025 trending-haircare-ingredients-2025-where-to-play
****Kline Physician-Dispensed Skincare – US Perception and Satisfaction Survey, October 2024
****** Results based on a 2025 24-week clinical test. Data on file at Obagi Cosmeceuticals LLC.
******* When compared to the untreated control group
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/ .
Media Contact:
obagi@purplepr.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d933d2c9-9897-4e5c-b9e1-8be7c88fe325
FAQ**
How does the launch of Nu-Cil ® BioStim™ Scalp Serum align with Waldencast Acquisition Corp. WALD's strategy to develop and scale purpose-driven beauty brands in a competitive market?
What clinical evidence supports the efficacy of Nu-Cil ® BioStim™ Scalp Serum, and how might this impact Obagi's market positioning under Waldencast Acquisition Corp. WALD?
With increasing demand for skincare-grade ingredients in hair care, how does Waldencast Acquisition Corp. WALD plan to leverage Obagi’s innovations like Nu-Cil ® BioStim™ to capture this growing consumer segment?
How does the pricing of Nu-Cil ® BioStim™ Scalp Serum at $125 reflect Waldencast Acquisition Corp. WALD's approach to positioning premium products in the beauty and wellness market?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-3.61% G/L:
$1.47 Last:
31,058 Volume:
$1.49 Open:
